• Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. 1999. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 16581667.
  • Federici MF, Kudryashov V, Saigo PE, Finstad CL, Lloyd KO. 1999. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer 81: 193198.
  • Gao S, Liu Q, Wang X, Lin B, Zhang S. 2010. Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med Oncol 27: 960967.
  • Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu Rev Med 53: 615627.
  • Hao YY, Lin B, Zhao Y, Zhang YH, Li FF, Diao B, Ou YL, Zhang SL. 2008. Alpha1,2-fucosyltransferase gene transfection influences on biological behavior of ovarian carcinoma-derived RMG-I cells. Fen Zi Xi Bao Sheng Wu Xue Bao 41: 435442.
  • Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. 2006. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res 66: 23382345.
  • Hazlehurst LA, Dalton WS. 2001. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20: 4350.
  • Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. 2001. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98: 18971903.
  • Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. 1990. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 50: 21832190.
  • Hodkinson PS, Mackinnon AC, Sethi T. 2007. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 83: 733741.
  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J Clin 57: 4366.
  • Kozlova NI, Morozevich GE, Chubukina AN, Berman AE. 2001. Integrin alphavbeta3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells. Oncogene 20: 47104717.
  • Liu J, Lin B, Hao Y, Qi Y, Zhu L, Li F, Liu D, Cong J, Zhang S, Iwamori M. 2009. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res 28: 154.
  • Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y, Zhu LC, Zhang SL, Iwamori M. 2010. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep 23: 833841.
  • Lu JG, Sun YN, Wang C, Jin de J, Liu M. 2009. Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation. Eur Arch Otorhinolaryngol 266: 8996.
  • Luqmani YA. 2005. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 ( Suppl 1): 3548.
  • Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG. 2005. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 7: R780787.
  • Maubant S, Cruet-Hennequart S, Poulain L, Carreiras F, Sichel F, Luis J, Staedel C, Gauduchon P. 2002. Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 97: 186194.
  • Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF. 2000. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 18: 22822292.
  • Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Naniwa J, Uegaki K, Nonaka M, Terakawa N. 2009. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 100: 546551.
  • Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C. 1999. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662668.
  • Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. 1999. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5: 15871594.
  • Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang CZ, Gao S, Liu SC, Zhang SL, Iwamori M. 2010. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie 92: 852857.
  • Zheng T, Wang J, Chen X, Liu L. 2010. Role of microRNA in anticancer drug resistance. Int J Cancer 126: 210.